New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas
Monitoring ctDNA levels provides highly specific, additional information enabling early recurrence detection in patients with translocation-associated sarcomas during the follow-up and can be integrated into clinical practice. However, MRD monitoring by ctDNA quantification alone does not allow the reliable detection of 100% of unilocular recurrences and should be complemented by the use of conventional imaging techniques.
Authors
- Martin Benesch (ORCID: https://orcid.org/0000-0001-7827-4130)
- Maria Anna Smolle (ORCID: https://orcid.org/0000-0003-1021-0899)
- Bernadette Liegl‐Atzwanger (ORCID: https://orcid.org/0000-0003-2229-5535)
- Markus G. Seidel (ORCID: https://orcid.org/0000-0003-0981-8661)
- Karl Kashofer (ORCID: https://orcid.org/0000-0002-5803-4014)
- Joanna Szkandera (ORCID: https://orcid.org/0000-0002-2217-893X)
- Andrea Thüringer
- Amin El‐Heliebi (ORCID: https://orcid.org/0000-0002-7679-6856)
- Andreas Leithner (ORCID: https://orcid.org/0000-0002-2598-2325)
- Sophie Joch
Institutions
- Medical University of Graz (AT)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1159/000543223
- Citations
- 1
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.29
Funders
- Amgen
- CSL Behring
- Eisai
- Medizinische Universität Graz
- PharmaMar